EVTCY / Evotec SE - ADR - SEC-Einreichungen, Jahresbericht, Proxy Statement

2

Exhibit 99.1 For further information, please contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, [email protected], M. +49.(0)151 70 688 784, www.evotec.com INTERIM STATEMENT 3M 2026 HIGHLIGHTS 4 MEASURED START TO THE YEAR: D&PD BROADLY IN LINE WITH 2025 DEVELOPMENT; JUST – EVOTEC BIOLOGICS SHOWS LOW SINGLE DIGIT GROWTH IN BASE BUSINESS1 4 SIGNIFICANT PROGRESS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2026 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off

Key figures of consolidated income statement & segment information

Exhibit 99.2 Evotec Announces First Quarter 2026 Results: Building Transformation Momentum · Q1 2026 financial performance: Full-year 2026 guidance confirmed; start to the year as expected with group revenues of €156.6 m (€166.9 m at CER); adj. Group EBITDA of -€21.9 m (-€18.9 m at CER) impacted by one-off effects and foreign exchange headwinds · D&PD partnerships progress: Nomination of a first p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026 COMMISSION FILE NUMBER 001-3404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o

Evotec Announces New Nomination to Board of Directors

Exhibit 99.1 Evotec Announces New Nomination to Board of Directors · Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilities · Conclusion of cooperation agreement with MAK Capital following constructive discussions, reflecting Evotec’s commitment to open shareholder dialogue · Annual General Meeting to vote on the appoi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026 COMMISSION FILE NUMBER 001-3404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o

Evotec Announces Chief Financial Officer Transition

Exhibit 99.1 Evotec Announces Chief Financial Officer Transition · Paul Hitchin to step down as of April 30, 2026 · Claire Hinshelwood appointed to CFO role as of May 1, 2026 Hamburg, Germany, April 24, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that Chief Financial Officer (CFO) Paul Hitchin will step down on April 30, 2026, for personal reasons unrelated to the

Key figures of consolidated income statement & segment information

Exhibit 99.1 Evotec Announces Fourth Quarter and Full-Year 2025 Results: Foundation for Profitable Growth • 2025 financial performance at high end of guidance: Q4 and FY group revenues of €253.3 m and €788.4 m, respectively (Q4: €266.7 m, FY: €810.4 m at CER); adj. group EBITDA of €58.0 m and €41.1 m, respectively (Q4: €64.8 m, FY: €52.3 m at CER) • Robust execution across key partnerships in D&PD

CONTENTS CLAUSE PAGE -i- #4853-4198-8303 SECTION 1 INTERPRETATION............................................................................................ 2 1. Definitions and Interpretation ........................................................

Exhibit 4.17 EXECUTION VERSION #4853-4198-8303 July 2024 EVOTEC SE (as the Company) EVOTEC SE (as Original Borrower and as Original Guarantor) COMMERZBANK AKTIENGESELLSCHAFT GOLDMAN SACHS LENDING PARTNERS LLC HSBC CONTINENTAL EUROPE S.A., GERMANY MORGAN STANLEY BANK AG UNICREDIT BANK GMBH (as Coordinating Bookrunners and Mandated Lead Arrangers) BNP PARIBAS S.A. NIEDERLASSUNG DEUTSCHLAND LANDESBAN

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Hitchin, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a materi

CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Christian Wojczewski, Chief Executive Officer of the Company,

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Christian Wojczewski, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st

Original Lender

Exhibit 4.9 Promissory Notes (Schuldscheindarlehen) The three promissory note loan agreements (collectively, the “Promissory Notes”) each govern an unsecured promissory note loan among Evotec SE, as borrower (the “Borrower”), Deutsche Bank AG and Landesbank Baden-Württemberg (“LBBW,” and, together with the Borrower and Deutsche Bank AG, the “Parties”), as arrangers and LBBW as the original lender.

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm Evotec SE Hamburg, Germany We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-260920 and 333-272285) of Evotec SE (the Company) of our reports dated April 2, 2026, relating to the consolidated financial statements, and the effectiveness of the Company’s internal control over f

Project Arboris Sale and Purchase Agreement 4 November 2025 2 137 Contents Clause Page Preamble ....................................................................................................................... 4 1. Sale and purchase of Shares .

Exhibit 4.19 4 November 2025 Evotec SE and Sandoz AG Agreement for the sale and purchase of all shares in Just Evotec Biologics EU (SAS) Project Arboris Sale and Purchase Agreement 4 November 2025 2 137 Contents Clause Page Preamble ....................................................................................................................... 4 1. Sale and purchase of Shares ..............

Group Policy on Insider Information 2 2. APPLICATION FIELD This Policy applies to all members of the Management and Supervisory Board as well as all other employees of the Company and its subsidiaries, including family members, household members and

Exhibit 11.1 1 Evotec Group Group Policy on Insider Information Document: Revision version No. 2 Effective Date: 19 April 2024 Author: Legal & Compliance Department Reviewed by: Management Board and Supervisory Board Approved by: Management Board and Supervisory Board on: 19 April 2024 Group Policy on Insider Information 1. PURPOSE ..................................................................

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026 COMMISSION FILE NUMBER 001-3404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

A r t i c l e s o f A s s o c i a t i o n of Evotec SE General Provisions § 1 Company and Registered Office

Exhibit 1.1 Non-binding convenience translation A r t i c l e s o f A s s o c i a t i o n of Evotec SE I. General Provisions § 1 Company and Registered Office (1)The name of the Company shall be: Evotec SE. (2)The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthet

European Union / Federal Republic of Germany

Exhibit 2.3 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of Evotec SE (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our artic

CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Hitchin, Chief Financial Officer of the Company, certify, pur

EVOTEC – Compensation Clawback Policy 2 executive officers who may from time to time be deemed subject to this Policy by the Supervisory Board or the Management Board (each, a “Covered Executive”).1 Financial Reporting Measures. is: (i) any measure t

Exhibit 10.1 Evotec Group Evotec Compensation Clawback Policy Document: Version No.3 Effective Date: December 1, 2023 Last Revised: February 19, 2026 Author: Global Legal & Compliance Reviewed By: Human Resources, Finance, and Governance Approved/Owned By: Evotec SE Supervisory Board Evotec Compensation Clawback Policy Table of Contents 1. Purpose ………………………………………………………….……………………………..………… 1 2. Scop

CONTENTS CLAUSE PAGE 1. Definitions and Interpretation ...................................................................... 3 2. Termination of SFA Finance Documents and global release .............................. 4 3. Local law specific releases

Exhibit 4.18 Execution Version 3 September 2025 EVOTEC SE EVOTEC INTERNATIONAL GMBH EVOTEC (HAMBURG) GMBH EVOTEC (FRANCE) SAS JUST-EVOTEC BIOLOGICS EU SAS APTUIT (VERONA) S.R.L. EVOTEC (UK) LIMITED APTUIT GLOBAL LLC EVOTEC (US), INC. JUST - EVOTEC BIOLOGICS, INC. as Security Grantors HSBC CONTINENTAL EUROPE S.A., GERMANY as Agent COMMERZBANK AKTIENGESELLSCHAFT as Security Agent Global Security Rel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026 COMMISSION FILE NUMBER 001-3404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o

Evotec Nominates Dieter Weinand as Supervisory Board Chairman

Exhibit 99.1 Evotec Nominates Dieter Weinand as Supervisory Board Chairman · Strengthens Supervisory Board leadership to support Evotec’s transformation, with a focus on commercial execution, strategic partnerships and profitability · Industry veteran brings more than 30 years of global pharmaceutical industry leadership experience across senior management, commercial, operational and strategic ro

Evotec to Receive Approx. $100 Million as Part of Tubulis Acquisition

Exhibit 99.2 Evotec to Receive Approx. $100 Million as Part of Tubulis Acquisition · Evotec participated in 2022 Series B financing round of antibody drug conjugate developer · Transaction marks continued execution of Evotec’s portfolio monetization strategy Hamburg, Germany, April 7, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that it is expected to receive appro

Evotec Announces ‘Horizon’ – Next Inflection in Its Strategic Transformation to Accelerate Growth and Promote Agility

Exhibit 99.1 Evotec Announces ‘Horizon’ – Next Inflection in Its Strategic Transformation to Accelerate Growth and Promote Agility · Horizon advances multi-stage transformation initiated with Priority Reset in 2024 and establishes new operating model across three pillars: operations, science and commercial execution · Operations: Global footprint further streamlined to 10 sites to simplify organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026 COMMISSION FILE NUMBER 001-3404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o

Notification of Major Holdings Page 1 | 5 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Ide

Exhibit 99.1 Notification of Major Holdings Page 1 | 5 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) Acquisition/disposal of share

Stimmrechtsmitteilung Seite 1 | 5 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Stimmrechtsmitteilung oder Korrektur einer Stimmrechtsmitteilung vom 1. Angaben zum Emittenten Name Legal Entity Identifier (LEI)

Exhibit 99.3 Stimmrechtsmitteilung Seite 1 | 5 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Stimmrechtsmitteilung oder Korrektur einer Stimmrechtsmitteilung vom 1. Angaben zum Emittenten Name Legal Entity Identifier (LEI) Straße, Hausnr. PLZ Ort 2. Grund der Mitteilung (mehrere Angaben möglich) X Erwerb bzw. Veräußerung von Aktien mit Stimmrechten X Erwerb

Notification of Major Holdings Page 1 | 5 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Ide

Exhibit 99.2 Notification of Major Holdings Page 1 | 5 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) Acquisition/disposal of share

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Ide

Exhibit 99.2 Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) Acquisition/disposal of share

Stimmrechtsmitteilung Seite 1 | 5 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Stimmrechtsmitteilung oder Korrektur einer Stimmrechtsmitteilung vom 1. Angaben zum Emittenten Name Legal Entity Identifier (LEI)

Exhibit 99.1 Stimmrechtsmitteilung Seite 1 | 5 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Stimmrechtsmitteilung oder Korrektur einer Stimmrechtsmitteilung vom 1. Angaben zum Emittenten Name Legal Entity Identifier (LEI) Straße, Hausnr. PLZ Ort 2. Grund der Mitteilung (mehrere Angaben möglich) X Erwerb bzw. Veräußerung von Aktien mit Stimmrechten X Erwerb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

Just – Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access

Exhibit 99.1 Just – Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access · Just – Evotec Biologics will optimize monoclonal antibodies (“mAbs”) and other biologic modalities · Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limited to: improved titer, pharmacokinetics, immunogenicity,

Page 2 | 4 6. Total positions % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1. + 7.b.2.) Total of both in % (7.a. + 7.b.) Total number of voting rights pursuant to Sec. 41 WpHG New 2,34 % 2

Exhibit 99.2 Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of sha

Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Ide

Exhibit 99.1 Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of sha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Ide

Exibit 99.2 Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of shar

6. Total positions % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1. + 7.b.2.) Total of both in % (7.a. + 7.b.) Total number of voting rights pursuant to Sec. 41 WpHG New 1,29 % 2,35 % 3,64

Exhibit 99.1 Notification of Major Holdings Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of shares with vo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

Page 2 | 5 6. Total positions % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1. + 7.b.2.) Total of both in % (7.a. + 7.b.) Total number of voting rights pursuant to Sec. 41 WpHG New 0,23 % 5

Exhibit 99.2 Notification of Major Holdings Page 1 | 5 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) Acquisition/disposal of share

Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations

Exhibit 99.1 Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations · Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment Hamburg, Germany, January 1, 2026: Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the appointment of Dr.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2026 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025 COMMISSION FILE NUMBER 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv

Evotec closes sale of Just – Evotec Biologics’ Toulouse site to Sandoz

Exhibit 99.1 Evotec closes sale of Just – Evotec Biologics’ Toulouse site to Sandoz • All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November • Agreement includes approximately US$ 350 m in cash for Just – Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec’s continuous man

Announcement pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 in conjunction with Article 2(1) of Delegated Regulation (EU) No. 2016/1052

Exhibit 99.1 Announcement pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 in conjunction with Article 2(1) of Delegated Regulation (EU) No. 2016/1052 Hamburg, 6 November 2025 – The management board of Evotec SE (Frankfurt Stock Exchange, ISIN: DE0005664809 and Nasdaq, ISIN: US30050E1055) resolved on 6 November 2025 to implement a share repurchase program. During the period from 7 Novem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025 COMMISSION FILE NUMBER 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025 COMMISSION FILE NUMBER 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv

In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules

Exhibit 99.1 In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules · Transaction showcases Evotec’s unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology · Accelerated implementation of strategy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025 COMMISSION FILE NUMBER 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv

2

Exhibit 99.1 interim STATEMENT 9M 2025 HIGHLIGHTS 4 CHANGE IN REVENUE MIX ALIGNED WITH NEW STRATEGY FOR LONG-TERM PROFITABLE GROWTH 4 DEMAND IN THE DISCOVERY & PRECLINICAL DEVELOPMENT (“D&PD”) SEGMENT STILL SOFT; JUST – EVOTEC BIOLOGICS (“JEB”) IS OUTPERFORMING EXPECTATIONS 4 EVOTEC SIGNS AGREEMENT WITH SANDOZ RESULTING IN PAYMENTS POTENTIALLY OVER US$ 650 M PLUS ROYALTIES ON PORTFOLIO OF UP TO 10

2

Exhibit 99.1 interim STATEMENT 6M 2025 HIGHLIGHTS  🞂 CHANGING REVENUE MIX ALIGNED WITH NEW STRATEGY FOR SUSTAINABLE PROFITABLE GROWTH  🞂 NAME OF REPORTING SEGMENT UPDATED TO BETTER REFLECT STRATEGIC FOCUS: DISCOVERY & PRECLINICAL DEVELOPMENT (D&PD, FORMER SHARED R&D), EFFECTIVE IMMEDIATELY; JUST – EVOTEC BIOLOGICS (JEB) UNCHANGED  🞂 CONTINUATION OF TRENDS SEEN SINCE START OF THE YEAR: D&PD BASE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 COMMISSION FILE NUMBER 001-340

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site

Exhibit 99.2 Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site · Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just – Evotec Biologics EU in Toulouse to Sandoz · Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines us

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces the signing of a non-binding agreement with Sand

Evotec adjusts revenue guidance and confirms profit guidance anticipating a more profitable revenue mix

Exhibit 99.2 Evotec adjusts revenue guidance and confirms profit guidance anticipating a more profitable revenue mix • Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec’s differentiated platforms • High-margin technology license revenues expected to have a stronger impact than anticipated • Significant cost opti

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec SE adjusts revenue guidance while confirming profit guidance Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Gu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 COMMISSION FILE NUMBER 001-34041

6-K 1 tm2521309d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of

All agenda items adopted

Exhibit 99.1 Evotec SE: Results of the Annual General Meeting 2025 • All agenda items adopted • Under the topic “Pioneering Drug Discovery” CEO Dr Christian Wojczewski presented Evotec’s current situation and strategic outlook • 46.45% of the registered share capital represented Hamburg, Germany, 03 June 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO)

Shared R&D

Exhibit 99.1 For further information, please contact: Volker Braun, EVP Head of Global Investor Relations & ESG, [email protected], M. +49.(0)40 228 999 338, www.evotec.com interim STATEMENT 3M 2025 HIGHLIGHTS 4 START TO THE YEAR AS ANTICIPATED: SHARED R&D WITH SIMILAR TREND AS 2024; JUST – EVOTEC BIOLOGICS WITH CONTINUING GROWTH MOMENTUM 4 SIGNIFICANT PROGRESS IN STRATEGIC PROTEIN DEGRADATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Christian Wojczewski, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st

Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results

Exhibit 99.1 Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results · Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth · Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence · Strong Q4

European Union / Federal Republic of Germany

Exhibit 2.3 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of Evotec SE (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our artic

Group Policy on Insider Information CONFIDENTIAL - This document is the confidential property of the Evotec group of companies and is for the sole use of members of Evotec staff. Page 2 of 9 2. APPLICATION FIELD This Policy applies to all members of

Exhibit 11.1 CONFIDENTIAL - This document is the confidential property of the Evotec group of companies and is for the sole use of members of Evotec staff. Page 1 of 9 Evotec Group Group Policy on Insider Information Document: Revision version No. 2 Effective Date: 19 April 2024 Author: Legal & Compliance Department Reviewed by: Management Board and Supervisory Board Approved by: Management Board

Evotec announces change in Management Board

Exhibit 99.1 Evotec announces change in Management Board • Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 • Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 Hamburg, Germany, 26 February 2025: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Financial Officer,

CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Christian Wojczewski, Chief Executive Officer of the Company,

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm Evotec SE Hamburg, Germany We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-260920 and No. 333-272285) of Evotec SE (the “Company”) of our reports dated April 14, 2025, relating to the consolidated financial statements, and the effectiveness of Evotec SE’s internal control o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 COMMISSION FILE NUMBER 001-3404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

Articles of Association of Evotec SE General Provisions § 1 Company and Registered Office

Exhibit 1.1 Non-binding convenience translation Articles of Association of Evotec SE I. General Provisions § 1 Company and Registered Office (1)The name of the Company shall be: Evotec SE. (2)The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthetic, semi-synthetic

Original Lender

Exhibit 4.9 Promissory Notes (Schuldscheindarlehen) The five promissory note loan agreements (collectively, the “Promissory Notes”) each govern an unsecured promissory note loan among Evotec SE, as borrower (the “Borrower”), Deutsche Bank AG and Landesbank Baden-Württemberg (“LBBW,” and, together with the Borrower and Deutsche Bank AG, the “Parties”), as arrangers and LBBW as the original lender.

CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Hitchin, Chief Financial Officer of the Company, certify, pur

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Hitchin, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a materi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 COMMISSION FILE NUMBER 001-3404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o

Evotec announces change in Management Board

EXHIBIT 99.1 Evotec announces change in Management Board · Dr Craig Johnstone steps down as Chief Operating Officer effective 31 December 2024 · Distribution of responsibilities internally Hamburg, Germany, 29 November 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 COMMISSION FILE NUMBER 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 COMMISSION FILE NUMBER 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Comment on withdrawn non-binding offer Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 COMMISSION FILE NUMBER 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

EXHIBIT 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Comment on media report Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) With respect to a media report, Evotec SE (“Company”) declares that it has received, without prior contact, a non-binding e

EVO / Evotec SE - Depositary Receipt (Common Stock) / Excalibur LuxCo SARL - SC 13D Activist Investment

SC 13D 1 d872020dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Evotec SE (Name of Issuer) Ordinary Shares, no par value per share (Title of Class of Securities) 30050E105* (CUSIP Number) Pierre-Alexandre Lechantre Triton GP HoldCo SARL 2, rue Edward Steichen L-2540 Luxembourg, Grand

[Signature page follows]

EX-10.2 3 d872020dex102.htm EX-10.2 Exhibit 10.2 UBS AG, London Branch 5 Broadgate London EC2M 2QS Triton V LuxCo 113 SARL 2 rue Edward Steichen Luxembourg City 2540 Luxembourg Date: 27 October 2024 Equity Swap Transaction Dear Sirs The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Equity Swap Transaction entered into between UBS AG, London Br

JOINT FILING AGREEMENT

EX-10.1 2 d872020dex101.htm EX-10.1 Exhibit 10.1 JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this joint filing agreement is attached, and any subsequent amendments thereto, and have duty

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 COMMISSION FILE NUMBER 001-34

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

Hamburg, 05 November 2024:

Exhibit 99.2 Evotec Announces Sale of API Manufacturing Facility to Monacum Partners · Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners · Transaction aligns with Evotec’s strategic optimization efforts, concentrating resources on key growth drivers · New ownership committed to maintaining and growing the business Hamburg, 05 November 2024: Evot

interim STATEMENT 9M 2024

Exhibit 99.1 For further information, please contact: Volker Braun, EVP Head of Global Investor Relations & ESG,[email protected], Phone +49 (0)40 228 999 338, Mobil +49.(0)40 228 999 338, www.evotec.com interim STATEMENT 9M 2024 HIGHLIGHTS 4 SUCCESSFUL EXTENSIONS AND EXPANSIONS OF STRATEGIC COLLABORATIONS WITH SANDOZ AND BMS 4 NEW PARTNERSHIP WITH NOVO NORDISK IN CELL THERAPY 4 GOOD ORDER T

HIGHLIGHTS } SECOND QUARTER INFLUENCED BY VOLATILITY IN SHARED R&D PORTFOLIO AND CAPACITY RAMP-UP OF J.POD TOULOUSE, FRANCE } IMPROVED ORDER INTAKE IN DISCOVERY NOT FULLY TRANSLATING INTO REVENUES IN 2024 } RESET FOR PROFITABLE GROWTH ON TRACK; FIRST

Exhibit 99.1 INTERIM STATEMENT 6M 2024 For further information, please contact: Volker Braun, EVP Head of Global Investor Relations & ESG, [email protected], M. +49.(0)151.1940 5058, www.evotec.com HIGHLIGHTS } SECOND QUARTER INFLUENCED BY VOLATILITY IN SHARED R&D PORTFOLIO AND CAPACITY RAMP-UP OF J.POD TOULOUSE, FRANCE } IMPROVED ORDER INTAKE IN DISCOVERY NOT FULLY TRANSLATING INTO REVENUES

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm Evotec SE Hamburg, Germany We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-260920 and No. 333-272285) of Evotec SE of our reports dated August 12, 2024, relating to the consolidated financial statements, and the effectiveness of Evotec SE’s internal control over financial r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Christian Wojczewski, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st

Evotec SE Global certificate for [·] bearer common stocks in the form of no-par stock Stock numbers: [·] to [·]

Exhibit 2.4 WKN: 566480 ISIN: DE0005664809 Reference number: [·] [·] no-par stock Evotec SE Hamburg Global certificate for [·] bearer common stocks in the form of no-par stock Stock numbers: [·] to [·] The bearer of this global certificate is a shareholder of Evotec SE, Hamburg, in accordance with its Articles of Association and holds [·] no-par stocks. The number of stocks issued and certificated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 COMMISSION FILE NUMBER 001-340

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

EVOTEC – Compensation Clawback Policy

Exhibit 10.1 Evotec Group Evotec Compensation Clawback Policy Evotec Compensation Clawback Policy Document: Version No.2 Table of Contents Effective Date: 1. Purpose 1 December 1, 2023 2. Scope 1 3. Key Definitions 1 4. Requirements 2 Author: 4.1 Recovery Triggered by Accounting Restatement 3 Global Legal & Compliance 4.2 Recovery Amount 3 4.3 No Recovery Required for De Minimis Amounts or Impract

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Laetitia Rouxel, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat

Execution version originally dated 29 December 2022, as amended and restated on 10 February 2023 2 WHEREAS: ........................................................................................................................................... 6

Exhibit 4.14 Contract number (FI No): 93512 Serapis No: 2021-0233 PROJECT JUSTICE Finance Contract originally dated 29 December 2022 between the European Investment Bank and Evotec SE as amended and restated on 10 February 2023 EIB Internal Classification Corporate Use Execution version originally dated 29 December 2022, as amended and restated on 10 February 2023 2 WHEREAS: ......................

EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT

Exhibit 4.16 EVOTEC US RSU PLAN AWARD AGREEMENT EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT This U.S. Restricted Share Unit Award Agreement (this “Agreement”) is entered into, effective as of 15 June 2023 (the “Grant Date”), by and between Evotec (the “Company”) and you (the “Participant”) pursuant and subject to the Evotec SE U.S. Restricted Share Unit Plan, as it may be amended fro

EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN

Exhibit 4.15 EVOTEC US RSU PLAN TERMS 2023 EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN 1. Introduction and Purpose. This U.S. Restricted Share Unit Plan (this “Plan”) was adopted by the Management Board by resolution dated 14 February 2023. Terms capitalized but not defined shall have the definitions set forth in Section 2. The purpose of this Plan is to set forth principles and rules, which govern

Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Christian Wojczewski, Chief Executive Officer of the Company,

European Union / Federal Republic of

Exhibit 2.3 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of Evotec SE (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our artic

30 July 2024 EVOTEC SE (as the Company) EVOTEC SE (as Original Borrower and as Original Guarantor) COMMERZBANK AKTIENGESELLSCHAFT GOLDMAN SACHS LENDING PARTNERS LLC HSBC CONTINENTAL EUROPE S.A., GERMANY MORGAN STANLEY BANK AG UNICREDIT BANK GMBH (as

Exhibit 4.17 EXECUTION VERSION 30 July 2024 EVOTEC SE (as the Company) EVOTEC SE (as Original Borrower and as Original Guarantor) COMMERZBANK AKTIENGESELLSCHAFT GOLDMAN SACHS LENDING PARTNERS LLC HSBC CONTINENTAL EUROPE S.A., GERMANY MORGAN STANLEY BANK AG UNICREDIT BANK GMBH (as Coordinating Bookrunners and Mandated Lead Arrangers) BNP PARIBAS S.A. NIEDERLASSUNG DEUTSCHLAND LANDESBANK BADEN-WÜRTT

Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Laetitia Rouxel, Chief Financial Officer of the Company, certify,

Original Lender

Exhibit 4.9 Promissory Notes (Schuldscheindarlehen) The five promissory note loan agreements (collectively, the “Promissory Notes”) each govern an unsecured promissory note loan among Evotec SE, as borrower (the “Borrower”), Deutsche Bank AG and Landesbank Baden-Württemberg (“LBBW,” and, together with the Borrower and Deutsche Bank AG, the “Parties”), as arrangers and LBBW as the original lender.

A r t i c l e s o f A s s o c i a t i o n of Evotec SE General Provisions § 1 Company and Registered Office

Exhibit 1.1 Non-binding convenience translation A r t i c l e s o f A s s o c i a t i o n of Evotec SE I. General Provisions § 1 Company and Registered Office (1) The name of the Company shall be: Evotec SE. (2)The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 COMMISSION FILE NUMBER 001-340

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

EVOTEC PROVIDES GUIDANCE UPDATE

Exhibit 99.2 EVOTEC PROVIDES GUIDANCE UPDATE • Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just – Evotec Biologics with mid double-digit revenue growth versus strong comparable basis • Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France • Further strengthened sales order book in Discovery is basis fo

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec SE provides guidance update Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its guidance for the fiscal year 2024. The Company expects Group revenues in the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off

Results of the Annual General Meeting 2024

EXHIBIT 99.1 Results of the Annual General Meeting 2024 · Most agenda items adopted with great majority · Annual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario Polywka Hamburg, Germany, 10 June 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its sh

EX-99.2

EXHIBIT 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off

For further information, please contact

Exhibit 99.1 For further information, please contact: Volker Braun, EVP Head of Global Investor Relations & ESG, [email protected], M. +49.(0)40 228 999 338, www.evotec.com interim STATEMENT 3M 2024 HIGHLIGHTS 4 CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTER 4 STRONG START WITH JUST – EVOTEC BIOLOGICS IN Q1 2024 4 POSI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-34041 CUSIP NUMBER 30050E105 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-34041 CUSIP NUMBER 30050E105 NOTIFICATION OF LATE FILING (Check One) ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran

EX-99.2

EXHIBIT 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of

EX-99.3

EXHIBIT 99.3

EX-99.1

EXHIBIT 99.1

EX-99.2

EXHIBIT 99.2

Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

EXHIBIT 99.1 Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer 23-Apr-2024 / 20:38 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/Tec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF April 2024 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF April 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF April 2024 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF April 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of

Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Ide

Exhibit 99.1 Notification of Major Holdings Page 1 | 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) Acquisition/disposal of share

EVTCY / Evotec SE - ADR / Novo Holdings A/S - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evotec SE (Name of Issuer) Ordinary Shares, no par value per share (Title of Class of Securities) 30050E105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2024 COMMISSION FILE NUMBER 001-340

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2024 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

Evotec announces CEO transition

EXHIBIT 99.1 Evotec announces CEO transition Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Board h

EX-99.2

EXHIBIT 99.2

Evotec Group 9M 2023

Exhibit 99.2 Evotec SE reports results for the first nine months 2023 and provides corporate update 4 CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS 4 PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS 4 PIPELINE PROGRESS, e.g. WITH ADVANCED ASSET IN NEURODEGENERATION 4 ALL ELEMENTS OF GUIDANCE CONFIRMED Hamburg, Germany, 08 November 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/T

interim STATEMENT 9M 2023

Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, [email protected], M. +49(0)151.1940 5058, www.evotec.com interim STATEMENT 9M 2023 HIGHLIGHTS 4 CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS 4 PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS 4 PIPELINE PROGRESS; E.G. WITH ADVANCED ASSET IN NEURODEGENERATION 4 ALL E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2023 COMMISSION FILE NUMBER 001-34

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023 COMMISSION FILE NUMBER 001-340

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

HALF-YEAR REPORT 2023

Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, [email protected], M. +49.(0)151.1940 5058, www.evotec.com HALF-YEAR REPORT 2023 I. MANAGEMENT REPORT 4 NEW AND EXTENDED ALLIANCES underline PIPELINE POTENTIAL 4 NEW GUIDANCE For full-year 2023 confIRMED HIGHLIGHTS Q2 CYBER-incident IMPACTING STRONG organic REVENUE GROWTH 4 Group

EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN

Exhibit 99.2 EVOTEC US RSU PLAN TERMS 2023 EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN 1. Introduction and Purpose. This U.S. Restricted Share Unit Plan (this “Plan”) was adopted by the Management Board by resolution dated 14 February 2023. Terms capitalized but not defined shall have the definitions set forth in Section 2. The purpose of this Plan is to set forth principles and rules, which govern

EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT

Exhibit 99.3 EVOTEC US RSU PLAN AWARD AGREEMENT EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT This U.S. Restricted Share Unit Award Agreement (this “Agreement”) is entered into, effective as of 15 June 2023 (the “Grant Date”), by and between Evotec (the “Company”) and you (the “Participant”) pursuant and subject to the Evotec SE U.S. Restricted Share Unit Plan, as it may be amended fro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2023 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off

EX-99.2

EXHIBIT 99.2

Evotec provides update on financial impact of cyber-attack

EXHIBIT 99.1 Evotec provides update on financial impact of cyber-attack Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it is adjusting its guidance for the fiscal year 2023. Due to the impact of the cyber-attack, the company now expects Group revenues in the range of € 750 – 790 m (previously

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off

Page 2 | 12 6. Total positions % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1. + 7.b.2.) Total of both in % (7.a. + 7.b.) Total number of voting rights pursuant to Sec. 41 WpHG New 3,29 %

Exhibit 99.1 Notification of Major Holdings Page 1 12 | Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of sh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off

EX-99.1

EXHIBIT 99.1

EX-99.2

EXHIBIT 99.2

EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN

Exhibit 10.1 EVOTEC US RSU PLAN TERMS 2023 EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN 1. Introduction and Purpose. This U.S. Restricted Share Unit Plan (this “Plan”) was adopted by the Management Board by resolution dated 14 February 2023. Terms capitalized but not defined shall have the definitions set forth in Section 2. The purpose of this Plan is to set forth principles and rules, which govern

TABLE OF CONTENTS

Exhibit 4.2 Execution Version TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Beneficial Owner 2 (e) CSB 2 (f) Custodian 2 (g) Deliver, execute, issue et al. 2 (h) Delivery Order 2 (i) Deposited Securities 2 (j) Direct Registration System 3 (k) Holder 3 (l) Securities Act of 1933 3 (m) Securities Excha

Calculation of Filing Fee Table Form S-8 (Form Type) Evotec SE (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Evotec SE (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, no par value p

EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT

Exhibit 10.2 EVOTEC US RSU PLAN AWARD AGREEMENT EVOTEC SE U.S. RESTRICTED SHARE UNIT PLAN AWARD AGREEMENT This U.S. Restricted Share Unit Award Agreement (this “Agreement”) is entered into, effective as of [ ] (the “Grant Date”), by and between Evotec (the “Company”) and you (the “Participant”) pursuant and subject to the Evotec SE U.S. Restricted Share Unit Plan, as it may be amended from time to

As filed with the Securities and Exchange Commission on May 30, 2023

As filed with the Securities and Exchange Commission on May 30, 2023 Registration No.

EX-99.1

EXHIBIT 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-34041

6-K 1 evo6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of

Consent of Independent Registered Public Accounting Firm

Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-260920) pertaining to the Employees’ Restricted Share Plan 2020 and Share Performance Plan 2017 of Evotec SE of our report dated July 9, 2021 (except for Note 3, to which the date is August 19, 2021), with respect to the consolidated fin

Original Lender

Exhibit 4.9 Promissory Notes (Schuldscheindarlehen) The five promissory note loan agreements (collectively, the “Promissory Notes”) each govern an unsecured promissory note loan among Evotec SE, as borrower (the “Borrower”), Deutsche Bank AG and Landesbank Baden-Württemberg (“LBBW,” and, together with the Borrower and Deutsche Bank AG, the “Parties”), as arrangers and LBBW as the original lender.

Page 2 | 11 6. Total positions % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1. + 7.b.2.) Total of both in % (7.a. + 7.b.) Total number of voting rights pursuant to Sec. 41 WpHG New 1,82 %

Exhibit 99.1 Notification of Major Holdings Page 1 | 11 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of sh

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm Evotec SE Hamburg, Germany We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-260920) of Evotec SE of our report dated May 10, 2023 relating to the consolidated financial statements and the effectiveness of Evotec SE’s internal control over financial reporting, which appears in

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Werner Lanthaler, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state

Evotec SE Global certificate for [●] bearer common stocks in the form of no-par stock Stock numbers: [●] to [●]

Exhibit 2.4 WKN: 566480 ISIN: DE0005664809 Reference number: [●] [●] no-par stock Evotec SE Hamburg Global certificate for [●] bearer common stocks in the form of no-par stock Stock numbers: [●] to [●] The bearer of this global certificate is a shareholder of Evotec SE, Hamburg, in accordance with its Articles of Association and holds [●] no-par stocks. The number of stocks issued and certificated

A r t i c l e s o f A s s o c i a t i o n of Evotec SE General Provisions § 1 Company and Registered Office

Exhibit 1.1 Non-binding convenience translation A r t i c l e s o f A s s o c i a t i o n of Evotec SE I. General Provisions § 1 Company and Registered Office (1)The name of the Company shall be: Evotec SE. (2)The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Eyotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lactitia Rouxel, Chief Financial Officer of the Company, certify,

European Union / Federal Republic of Germany

Exhibit 2.3 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of Evotec SE (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our artic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-34041 E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive offi

Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Werner Lanthaler, Chief Executive Officer of the Company, cert

Execution version originally dated 29 December 2022, as amended and restated on 10 February 2023 2 WHEREAS: ........................................................................................................................................... 6

Exhibit 4.14 Contract number (FI No): 93512 Serapis No: 2021-0233 PROJECT JUSTICE Finance Contract originally dated 29 December 2022 between the European Investment Bank and Evotec SE as amended and restated on 10 February 2023 EIB Internal Classification Corporate Use &(57$,1,'(17,),(',1)250$7,21+$6%((1(;&/8'(')5207+((;+,%,7%(&$86(,7,6 %27+ L 1270$7(5,$/$1' LL :28/'/,.(/<&$86(&203(7,7,9(+$50727+

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I. Laetitia Rouxel, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat

Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing

EXHIBIT 99.2

Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz

EXHIBIT 99.1 Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., has entered a multi-year, long-term tech partnership with Sandoz for the immediate development and subs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive offi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

NT 20-F 1 tm2311375d2nt20f.htm NT 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34041 CUSIP NUMBER 30050E105 (Check one): ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F

Cyber Attack on Evotec

EX-99.1 2 evoex991.htm CYBER ATTACK ON EVOTEC EXHIBIT 99.1 Cyber Attack on Evotec 07-Apr-2023 / 15:10 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2023 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 COMMISSION FILE NUMBER 001-3404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive o

Page 2 | 5 6. Total positions % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1. + 7.b.2.) Total of both in % (7.a. + 7.b.) Total number of voting rights pursuant to Sec. 41 WpHG New 5,002936

Exhibit 99.1 Notification of Major Holdings Page 1 | 5 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of sha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2023 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of

Evotec SE: Ahead of the curve – Leadership in our focus areas for medicines that matter

EXHIBIT 99.2

28 March 2023

EXHIBIT 99.1 28 March 2023 Ad hoc release according to Article 17 MAR of the Regulation (EU) No 596/2014 Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the Company has extended and expanded its strategic partnership with Bris

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2023 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive of

Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership

EXHIBIT 99.2

Evotec SE preliminary fiscal year 2022 results: “Ahead of the curve” – very strong performance in a challenging year

EXHIBIT 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2023 COMMISSION FILE NUMBER 001-34

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2023 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

1

EXHIBIT 99.1 Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer 07.02.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, 07 February 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as

EVTCY / Evotec AG / Novo Holdings A/S - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Evotec SE (Name of Issuer) Ordinary Shares, no par value per share (Title of Class of Securities) 30050E105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p

| Page 2 4 6. Total positions % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1. + 7.b.2.) Total of both in % (7.a. + 7.b.) Total number of voting rights pursuant to Sec. 41 WpHG New 10,11 %

Exhibit 99.1 Notification of Major Holdings | Page 1 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of sha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 COMMISSION FILE NUMBER 001-3

6-K 1 tm2230613d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 5608

interim STATEMENT 9M 2022

Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, [email protected], T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com interim STATEMENT 9M 2022 HIGHLIGHTS 4 multiple new and extended alliances in all areas 4 Paradigm shift in biologics Starting its market entry Strategy 4 commercial launch of next-generation multi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 COMMISSION FILE NUMBER 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 COMMISSION FILE NUMBER 001-34

6-K 1 tm2227728d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 56081

| Seite 2 3 6. Gesamtstimmrechtsanteile Anteil Stimmrechte (Summe 7.a) Anteil Instrumente (Summe 7.b.1 + 7.b.2) Summe Anteile (Summe 7.a + 7.b) Gesamtzahl der Stimmrechte nach § 41 WpHG neu 1,64 % 0,00 % 1,64 % 176.952.653 letzte Mitteilung 4,77 % 0,

EX-99.1 2 tm2227728d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Stimmrechtsmitteilung | Seite 1 3 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Stimmrechtsmitteilung oder Korrektur einer Stimmrechtsmitteilung vom 1. Angaben zum Emittenten Name Legal Entity Identifier (LEI) Straße, Hausnr. PLZ Ort 2. Grund der Mitteilung (mehrere Angaben möglich) X Erwerb bzw. Verä

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 COMMISSION FILE NUMBER 001-340

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant?s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive

HALF-YEAR REPORT 2022

Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, [email protected], T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com HALF-YEAR REPORT 2022 I. MANAGEMENT REPORT 4 NEW AND EXTENDED ALLIANCES underline success of GROWTH STRATEGY 4 Acquisition expands capabilities and Expertise in cell therapy 4 Guidance for full-yea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041

6-K 1 tm2219410d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (

Notification of Major Holdings | Page 1 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Ide

EX-99.1 2 tm2219410d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Notification of Major Holdings | Page 1 4 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple re

Evotec SE reports results of Annual General Meeting 2022

EXHIBIT 99.1 Evotec SE reports results of Annual General Meeting 2022 · ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY · CAMILLA MACAPILI LANGUILLE ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD; KASIM KUTAY RESIGNS FROM SUPERVISORY BOARD · AUTHORISED CAPITAL 2022 RESOLVED · REVISED REMUNERATION SYSTEM FOR MANAGEMENT BOARD APPROVED Hamburg, Germany, 22 June 2022: Evotec SE (Frankfurt Stock Ex

Annual General Meeting 2022 Voting Results

EXHIBIT 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2022 COMMISSION FILE NUMBER 001-34041

6-K 1 evo6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address o

Notification of Major Holdings | Page 1 11 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Id

EX-99.1 2 tm2218076d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Notification of Major Holdings | Page 1 11 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041

6-K 1 tm2218076d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (

Notification of Major Holdings | Page 1 11 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Id

EX-99.1 2 tm2217889d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Notification of Major Holdings | Page 1 11 Hamburg 22419 Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041

6-K 1 tm2217889d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041

6-K 1 tm2217690d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (

Notification of Major Holdings | Page 1 3 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address

EX-99.1 2 tm2217690d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Notification of Major Holdings | Page 1 3 Hamburg 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for no

Guidance 2022

Exhibit 99.1 For further information, please contact: Volker Braun, SVP Global Head of Investor Relations & ESG, [email protected], T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com INTERIM STATEMENT Q1 2022 HIGHLIGHTS 4 Strong performance leads to SIGNIFICANT revenue growth 4 Strong momentum in all BUSINESS areas 4 New partnerships BASED on Data-driven precision medicine PLAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 COMMISSION FILE NUMBER 001-34041

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant?s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of principal executive off

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2022 COMMISSION FILE NUMBER 001-34041

6-K 1 evo6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address of

Evotec and Bristol Myers Squibb extend and expand strategic partnership

EX-99.1 2 evoex991.htm EVOTEC AND BRISTOL MYERS SQUIBB EXTEND AND EXPAND STRATEGIC PARTNERSHIP EXHIBIT 99.1 Evotec and Bristol Myers Squibb extend and expand strategic partnership Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the Company has extended and expanded its partnership with Bristol Myers Squi

Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation

EX-99.2 3 evoex992.htm EVOTEC AND BRISTOL MYERS SQUIBB EXTEND AND EXPAND STRATEGIC PARTNERSHIP IN PROTEIN DEGRADATION EXHIBIT 99.2

Description of Securities.

Exhibit 2.3 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of Evotec SE (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our artic

Certification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Werner Lanthaler, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

Company’s Specimen Certificate for Ordinary Shares.

EX-2.4 4 evo-20211231xex2d4.htm EXHIBIT 2.4 Exhibit 2.4 WKN: 566480 ISIN: DE0005664809 Reference number: [●] [●] no-par stock Evotec SE Hamburg Global certificate for [•] bearer common stocks in the form of no-par stock Stock numbers: [●] to [●] The bearer of this global certificate is a shareholder of Evotec SE, Hamburg, in accordance with its Articles of Association and holds [●] no-par stocks.

Articles of Association of Evotec SE.

Non-binding convenience translation ? Exhibit 1.1 ? A r t i c l e s o f A s s o c i a t i o n ? of Evotec SE ? ? ? I. General Provisions ? ? 1 Company and Registered Office ? (1)The name of the Company shall be: ? Evotec SE. ? (2)The registered office of the Company shall be in Hamburg. ? ? 2 Object of the Company ? (1) The object of the Company shall be research activities in the field of biologi

Certification of Principal Executive Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Werner Lanthaler, Chief Executive Officer of the Company, cert

Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Enno Spillner, certify that: 1. I have reviewed this annual report on Form 20-F of Evotec SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mater

Letter from Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft to the U.S. Securities and Exchange Commission, dated April 26, 2022

EX-16.1 13 evo-20211231xex16d1.htm EXHIBIT 16.1 Exhibit 16.1 April 26, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Evotec SE pursuant to the third paragraph of Item 16F of Form 20-F (copy attached), which we understand will be filed with the Securities and Exchange Commission on April 26, 2021. We agree w

Consent of Independent Registered Public Accounting Firm EY

Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-260920) pertaining to the Employees? Restricted Share Plan 2020 and Share Performance Plan 2017 of Evotec SE of our report dated July 9, 2021 (except for Note 4, to which the date is August 19, 2021), with respect to the consolidated fin

Certification of Principal Financial Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Evotec SE (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Enno Spillner, Chief Financial Officer of the Company, certify, pu

Stock Option Plan and Share Performance Plan 2017 for Management.

EX-4.5 5 evo-20211231xex4d5.htm EXHIBIT 4.5 Exhibit 4.5 Share Performance Plan 2017 Terms and Conditions for EVOTEC’s Management Board Grant Date: 28 January 2022 Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Annual Grant 3 § 3 Vesting Period 4 § 4 Performance Measurement Period 4 § 5 Key Performance Indicators 4 § 6 Exercise

Consent of Independent Registered Public Accounting Firm BDO.

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statement on Form S8 (No. 333-260920) of Evotec SE of our report dated April 25, 2022, relating to the consolidated financial statements which appears in this Form 20-F. /s/ BDO AG Wirtschaftsprüfungsgesellschaft Frankfurt am Main, Germany April 26, 2022

Evotec SE: Setting the pace… Bringing Probabilities of Success up with the right platforms & technologies

EX-99.2 3 evoex992.htm EX 99.2 EXHIBIT 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2022 COMMISSION FILE NUMBER 001-34041

6-K 1 evo6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Address

Guidance 20221) at constant fx

EXHIBIT 99.1 Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures · STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE · DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES · SUBSTANTIALLY STRENGTHENED BALANCE SHEET PROVIDING VERY GOOD FOUNDATION AND LEVERAGE FOR SUSTAINABLE, LO

Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets

EX-99.1 2 evoex991.htm EX-99.1 EXHIBIT 99.1 Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by Bayer about a decision to discontinue the development of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2022 COMMISSION FILE NUMBER 001-34

6-K 1 evo6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2022 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 560810 (Addre

EVTCY / Evotec AG / Novo Holdings A/S - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evotec SE (Name of Issuer) Ordinary Shares (Title of Class of Securities) 30050E105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

JOINT FILING AGREEMENT

EX-99.1 2 ss616499ex9901.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among all the undersigned that the Schedule 13D filed on or about this date and any amendments thereto with respect to the beneficial ownership by the undersigned of ordinary shares, no par value, of Evotec SE is being filed on behalf of each of the undersigned in accordan

EVTCY / Evotec AG / Mubadala Investment Co PJSC - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Evotec SE (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 30050E105(1) (CUSIP Number) Mubadala Investment Company PJSC Attention: Treasury and Investor Relations P.O. Box 45005 Abu Dhabi United Arab Emirates +971 2 413 0000 (

[email protected], T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com

EX-99.1 2 tm2131300d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For further information, please contact: Volker Braun, SVP Global Head of Investor Relations & ESG, [email protected], T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com INTERIM STATEMENT 9M 2021 HIGHLIGHTS 4 Strong operational performance leads to SIGNIFICANT revenue growth 4 Co-owned pipeline gaining momentum 4 j.pod®

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 COMMISSION FILE NUMBER 001-3

6-K 1 tm2131300d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 COMMISSION FILE NUMBER 001-34041 Evotec SE (Translation of registrant’s name into English) Essener Bogen 7 22419 Hamburg Germany Tel: +49 40 5608

Articles of Association of Evotec SE.

Exhibit 3.1 A r t i c l e s o f A s s o c i a t i o n of Evotec SE I. General Provisions § 1 Company and Registered Office (1) The name of the Company shall be: Evotec SE. (2) The registered office of the Company shall be in Hamburg. § 2 Object of the Company (1) The object of the Company shall be research activities in the field of biologically functional synthetic, semi-synthetic, and natural ac

Stock Option Plan and Share Performance Plan 2017 for Management.

EX-10.4 7 d233559dex104.htm EX-10.4 Exhibit 10.4 Restricted Share Plan 2020 Terms and Conditions for EVOTEC’s Management Board Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Biannual Grant of Awards 3 § 3 Waiting Period and Exercise Period 4 § 4 Performance Period 4 § 5 Key Performance Indicator 4 § 6 Exercisable Restricted Sh

Stock Option Plan and Share Performance Plan 2017 for Senior Executives.

Exhibit 10.3 Share Performance Plan 2017 Terms and Conditions for EVOTEC’s Senior Executives Evotec AG Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Annual Grant 3 § 3 Vesting Period 4 § 4 Performance Measurement Period 4 § 5 Key Performance Indicators 4 § 6 Exercise of Shares 5 § 7 Termination of employment contract 7 § 8 Change of Co

Restricted Share Plan 2020 for Management.

EX-10.1 4 d233559dex101.htm EX-10.1 Exhibit 10.1 Restricted Share Plan 2020 Terms and Conditions for EVOTEC’s Management Board Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Biannual Grant of Awards 3 § 3 Waiting Period and Exercise Period 4 § 4 Performance Period 4 § 5 Key Performance Indicator 4 § 6 Exercisable Restricted Sh

Restricted Share Plan 2020 for Non-Management.

EX-10.2 5 d233559dex102.htm EX-10.2 Exhibit 10.2 Restricted Share Plan 2020 Terms and Conditions Evotec SE Manfred Eigen Campus Essener Bogen 7 22419 Hamburg, Germany List of Content Objectives § 1 Eligibility 3 § 2 Biannual Grant of Awards 3 § 3 Waiting Period and Exercise Period 4 § 4 Performance Period 4 § 5 Key Performance Indicator 4 § 6 Exercisable Restricted Share Awards 4 § 7 Exercise of S

As filed with the Securities and Exchange Commission on November 9, 2021

S-8 1 d233559ds8.htm S-8 As filed with the Securities and Exchange Commission on November 9, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evotec SE (Exact name of registrant as specified in its charter) Federal Republic of Germany Not Applicable (State of incorporation or organizati

20,000,000 American Depositary Shares Representing 10,000,000 Ordinary Shares

Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-260143 PROSPECTUS 20,000,000 American Depositary Shares Representing 10,000,000 Ordinary Shares This is the initial public offering of American Depositary Shares, or ADSs, representing 10,000,000 ordinary shares of Evotec SE. We are offering 20,000,000 ADSs at an initial public offering price of $21.75 per ADS. The closing pri

REDACTED EXHIBIT

CERT

EVOTEC SE Essener Bogen 7 22419 Hamburg November 1, 2021

CORRESP 1 filename1.htm EVOTEC SE Essener Bogen 7 22419 Hamburg Germany November 1, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tracey Houser, Brian Cascio, Dillon Hagius, Suzanne Hayes Re: Evotec SE Registration Statement on Form F-1 File No. 333-260143 Dear Ms. Houser, Mr. Cascio, Mr. Ha

BOFA SECURITIES, INC. One Bryant Park New York, New York 10036

CORRESP 1 filename1.htm BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 MORGAN STANLEY & CO. LLC 1585 Broadway New York, New York 10036 Via EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 November 1, 2021 Attention: Tracey Houser Brian Cascio Dillon Hagius Suzanne

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Evotec SE (Exact name of registrant as specifie

8-A12B 1 d236556d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Evotec SE (Exact name of registrant as specified in its charter) Federal Republic of Germany Not Applicable (State of incorporation or organization) (I.R.S. Employ

Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 October 29, 2021 VIA EDGAR Securities and Exchan

CORRESP 1 filename1.htm Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 October 29, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Trace

As filed with the Securities and Exchange Commission on October 29, 2021.

F-1/A 1 d166695df1a.htm F-1/A Table of Contents As filed with the Securities and Exchange Commission on October 29, 2021. Registration No. 333-260143 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evotec SE (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation o

LETTER

United States securities and exchange commission logo October 28, 2021 Werner Lanthaler Chief Executive Officer Evotec AG Essener Bogen 7 22419 Hamburg Germany Re: Evotec AG Amendment No.

Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900

CORRESP 1 filename1.htm Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 October 28, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Trace

As filed with the Securities and Exchange Commission on October 28, 2021.

Table of Contents As filed with the Securities and Exchange Commission on October 28, 2021.

Form of Underwriting Agreement.

Exhibit 1.1 Evotec SE (a European stock corporation organized under the laws of the Federal Republic of Germany and the European Union) [ ? ] American Depositary Shares Each Representing One-Half of One Ordinary Share in Bearer Form (no par value per share) UNDERWRITING AGREEMENT Dated: [ ? ], 2021 Evotec SE (a European stock corporation organized under the laws of Federal Republic of Germany and

Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 October 26, 2021

CORRESP 1 filename1.htm Sophia Hudson, P.C. To Call Writer Directly: +1 212 446 4750 [email protected] 601 Lexington Avenue New York, NY 10022 United States +1 212 446 4800 www.kirkland.com Facsimile: +1 212 446 4900 October 26, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Trace

As filed with the Securities and Exchange Commission on October 26, 2021.

Table of Contents As filed with the Securities and Exchange Commission on October 26, 2021.